|
Asthma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Low FENO asthmatics had near normal iNOS and ARG2 expression (both P > 0.05), and significantly higher PC20 (P < 0.001) as compared to high FENO asthmatics.
|
28797075 |
2017 |
|
Asthma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
To determine the relationships of iNOS expression/activation and arginase 2 expression with asthma severity, FeNO, nitrotyrosine (NT) and eosinophilic inflammation.
|
22092728 |
2012 |
|
Asthma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
The elevated arginase II activity and expression may be a mechanism underlying adverse effects induced by PM exposure in asthma patients.
|
22712848 |
2012 |
|
Asthma
|
0.390 |
Biomarker
|
disease |
BEFREE |
DNA methylation in ARG1 and ARG2 is associated with FeNO in children with asthma and suggests a possible role for epigenetic regulation of nitric oxide production.
|
21512169 |
2011 |
|
Asthma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Two polymorphisms in arginase 2 (rs17249437 and rs3742879) were associated with asthma and with more severe airway obstruction.
|
20124949 |
2010 |
|
Asthma
|
0.390 |
Biomarker
|
disease |
CTD_human |
Compared with the most common haplotype within each locus, 1 ARG1 haplotype was associated with reduced risk (odds ratio [OR] per haplotype copy, 0.55; 95% CI, 0.36-0.84), and 1 ARG2 haplotype was associated with increased risk (OR per haplotype copy, 1.35; 95% CI, 1.04-1.76) of asthma.
|
19281908 |
2009 |
|
Asthma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Compared with the most common haplotype within each locus, 1 ARG1 haplotype was associated with reduced risk (odds ratio [OR] per haplotype copy, 0.55; 95% CI, 0.36-0.84), and 1 ARG2 haplotype was associated with increased risk (OR per haplotype copy, 1.35; 95% CI, 1.04-1.76) of asthma.
|
19281908 |
2009 |
|
Asthma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Carrying 2 copies of minor alleles for either of 2 highly associated ARG2 SNPs was associated with a statistically significant increased relative risk (RR) of asthma (1.5, 95% CI = 1.1-2.1 for arg2s1; RR = 1.6, 95% CI = 1.1-2.3 for arg2s2).
|
16387594 |
2006 |
|
Asthma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Microarray analysis of the expression profiles of lung tissue in two murine models of asthma revealed high levels of arginase I and arginase II activity, in association with IL-4 and IL-13 overexpression, suggesting that arginine pathways are critical in the pathogenesis of asthma.
|
12813015 |
2003 |
|
Asthma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Genes related to metabolism of basic amino acids, specifically the cationic amino acid transporter 2, arginase I, and arginase II, were particularly prominent among the asthma signature genes.
|
12813022 |
2003 |
|
Malignant neoplasm of prostate
|
0.320 |
Biomarker
|
disease |
CTD_human |
In contrast to prostate cancer, ARG2 expression was rarely demonstrated in PDC cells by immunohistochemistry, and instead ARG2 was characteristically expressed in α-smooth muscle actin-positive cancer-associated fibroblasts (CAFs), especially those located within and around necrotic areas in PDC.
|
23424623 |
2013 |
|
Malignant neoplasm of prostate
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
In this report, we demonstrate that both ARG1 and ARG2 are expressed by hormone-sensitive (HS) and hormone-refractory (HR) PCa cell lines, with the LNCaP cells having the highest arginase activity.
|
20711410 |
2010 |
|
Malignant neoplasm of prostate
|
0.320 |
Biomarker
|
disease |
BEFREE |
Arginase 2, inducible- and endothelial-nitric-oxide synthase (iNOS and eNOS), indoleamine 2,3-dioxygenase (IDO) and TGF-beta, might impair immune functions in prostate cancer (PCA) patients.
|
18619832 |
2008 |
|
Prostatic Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer.
|
23424623 |
2013 |
|
Carcinoma, Pancreatic Ductal
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Here we studied the expression of ARG2 in pancreatic ductal carcinoma (PDC) tissue clinicopathologically by examining over 200 cases of PDC.
|
23424623 |
2013 |
|
Carcinoma, Pancreatic Ductal
|
0.310 |
Biomarker
|
disease |
CTD_human |
Here we studied the expression of ARG2 in pancreatic ductal carcinoma (PDC) tissue clinicopathologically by examining over 200 cases of PDC.
|
23424623 |
2013 |
|
Prostatic Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
Expression of arginase II in prostate cancer.
|
18202758 |
2008 |
|
Nerve Degeneration
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Collectively, our results show that deletion of A2 limits ONC-induced neurodegeneration and glial activation, and enhances axonal sprouting by a mechanism involving increases in BDNF and decreases in retinal inflammation.
|
30618589 |
2018 |
|
Retinal Degeneration
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Retinal Neuroprotection From Optic Nerve Trauma by Deletion of Arginase 2.
|
30618589 |
2018 |
|
Pulmonary Hypertension
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
These novel data support the notion that resveratrol may be a potential therapeutic agent in pulmonary hypertension by preventing PASMC arginase II induction and proliferation.
|
24951775 |
2014 |
|
Necrosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
In contrast to prostate cancer, ARG2 expression was rarely demonstrated in PDC cells by immunohistochemistry, and instead ARG2 was characteristically expressed in α-smooth muscle actin-positive cancer-associated fibroblasts (CAFs), especially those located within and around necrotic areas in PDC.
|
23424623 |
2013 |
|
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer.
|
23424623 |
2013 |
|
Hypertensive disease
|
0.220 |
Biomarker
|
group |
BEFREE |
Plasmatic Concentrations of ADMA and Homocystein in Llama (<i>Lama glama</i>) and Regulation of Arginase Type II: An Animal Resistent to the Development of Pulmonary Hypertension Induced by Hypoxia.
|
29896110 |
2018 |
|
Hypertensive disease
|
0.220 |
Biomarker
|
group |
RGD |
An upregulation of arginase type II could be pivotal in understanding the pathogenesis of systolic hypertension and probably other phenomena associated with intermittent hypobaric hypoxia.
|
20039818 |
2009 |
|
Hypertensive disease
|
0.220 |
Biomarker
|
group |
RGD |
Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat.
|
18475148 |
2008 |